This article is more than 5 years old. Information may no longer be current.
Rapid Response from London 2014
Evaluating Emerging IFN-Free Treatment Regimens for HCV.
Click Here to Manage Email Alerts
Chronic hepatitis C virus infection is a leading cause of cirrhosis, end-stage liver disease, hepatocellular carcinoma, and death from liver disease in the United States. Effective management of HCV continues to pose a challenge for health care practitioners. The discovery, development, and availability of direct-acting antiviral agents (DAAs) offer new treatment options and the possibility of improved outcomes for newly diagnosed patients as well as those who have experienced a relapse or failed to respond to previous treatment. Rapid advancements in the field and new interferon-free regimens on the horizon for HCV genotype 1 patients offer improvements in outcomes, shorter treatment durations, and unique adverse event profiles; therefore, clinicians must stay informed of the evolving data in order to counsel patients appropriately. In the near future, clinicians will face challenges regarding how to select interferon-containing versus interferon-free regimens for HCV genotype 1 patients, and how to make treatment choices among the potentially numerous interferon-free regimens. This roundtable discussion among leading experts in HCV was recorded immediately following the 2014 EASL meeting in London, England, and will explore some of the most recent findings and address the evidence-based clinical application of these data for HCV patients.
Learning Objectives:
At the conclusion of this activity, participants should be able to:
- Assess evidence-based clinical data on the safety and efficacy of all-oral investigational regimens, with and without ribavirin, currently being studied to treat HCV to assist in current and future clinical decision-making.
- Identify the different mechanisms of action of the various DAA classes and describe the rationale for interferon-free combinations under investigation for different patient groups.
Click here to see this Education Lab activity.
Overview
Author(s)/Faculty: Mark Sulkowski, MD; Graham R. Foster, FRCP, PhD; Jordan Feld, MD, MPH; Stefan Zeuzem, MDSource: Healio Gastroenterology Education Lab
Type: Multimedia
Articles/Items: 3
Release Date: 7/2/2014
Expiration Date: 7/1/2015
Credit Type: CME
Number of Credits: 1
Cost: Free
Provider: Keck School of Medicine of USC
CME Information
Provider Statement: This continuing medical education activity is provided by Keck School of Medicine of USCEducational Partner: Vindico Medical Education
Support Statement: This activity is supported by an educational grant from AbbVie.
Target Audience: The intended audience for the activities is gastroenterologists, hepatologists, and other health care professionals involved in the treatment of patients with hepatitis C virus (HCV).